Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Dietary fibre seems to have a relevant role in body weight management. In an acute study the investigators found that high viscous-high gelling pectin increased feelings of satiety. The objective of this study is to study the effects of 2 weeks of supplementation of high gelling-high viscous fibre or a high gelling-high viscous non-fibre control on energy intake.
The investigators do this by measuring the difference in ad libitum energy intake after 15 days of pectin or 15 days of control supplements. The investigators will further measure differences in 24h feelings of satiety, fasting blood glucose and insulin, fermentation and composition of microbiota.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| pectin | Experimental | 10 gram high gelling-high viscous fiber, added to a drink |
|
| control | Placebo Comparator | 10g gelatin, added to a drink |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| LM pectin (10%) | Dietary Supplement | 15 days 1 daily consumption of a drink with 10g pectin added |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Energy intake | after 14 days of both intervention and placebo supplements ad libitum energy intake is measured for 3 days in a row. The change in energy intake will be calculated. | change from placebo after 2 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| satiety | at day 1 and after 15 days of both supplement and placebo intake satiety is measured hourly over 1 day at waking hours. The change in satiety will be calculated. | change from placebo after 1 day and 15 days |
| fasting glucose |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Edith Feskens, Prof | Wageningen University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Wageningen University | Wageningen | 7002HD | Netherlands |
Not provided
| ID | Term |
|---|---|
| D018761 | Multiple Endocrine Neoplasia Type 1 |
| ID | Term |
|---|---|
| D009377 | Multiple Endocrine Neoplasia |
| D004701 | Endocrine Gland Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
Not provided
Not provided
| ID | Term |
|---|---|
| D005780 | Gelatin |
| ID | Term |
|---|---|
| D012596 | Scleroproteins |
| D011506 | Proteins |
| D000602 | Amino Acids, Peptides, and Proteins |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| gelatin |
| Dietary Supplement |
15 days 1 daily consumption of a drink with 10g gelatin added |
|
at day 0, 1 and day 15 of supplementation period fasting glucose is measured
| change from placebo after day 0, 1 and 15 |
| fasting insulin | at day 0, 1 and day 15 of supplementation period fasting insulin is measured | change from placebo after day 0, 1 and 15 |
| fasting leptin | at day 0, 1 and day 15 of supplementation period fasting leptin is measured | change from placebo after day 0, 1 and 15 |
| hydrogen in breath | at day 2 and at day 15 hydrogen is measured hourly over 1 day at waking hours | change from placebo after day 2 and 15 |
| energy intake | before supplement intake and after 1 day of supplement 1-day ad libitum energy intake is measured. The change in energy intake will be calculated. | change from placebo after day 0 and 1 |
| body weight | Each day the subject reports to the research center, body weight is measured. The change in body weight compared to placebo will be calculated. | change from placebo after day 0,1,2,14,15, 16 and 17 |
| adverse events | participants will be asked to register adverse events daily in a diary. They are also asked to report ae's to the researchers. number and type of AEs after fibre supplements will be compared to number and type of AEs after placebo supplements | daily from day 0 to day 16 |
| D009378 |
| Neoplasms, Multiple Primary |
| D009386 | Neoplastic Syndromes, Hereditary |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D004700 | Endocrine System Diseases |